esmo 2023 presentation guidelines

Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements:  Google Chrome 24+ ,  Mozilla Firefox 20+ ,  Internet Explorer 11 ,  Opera 15–18 ,  Apple Safari 7 ,  SeaMonkey 2.15-2.23

• Meeting Calendar
• OncologyPRO
• Meeting Resources

ESMO Gynaecological Cancers Congress 2023

23 - 24 Feb 2023

Barcelona, Spain

Slides and webcasts from ESMO Gynaecological Cancers Congress 2023 are available to ESMO Members and registered delegates, according to the presenters' agreement to release them. Abstracts and ePosters are open to all.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

This event provides insights into the diagnosis, biology and therapy of gynaecological malignancies, and updates on state-of-the-art expert management of patients with gynaecological cancers. The programme content highlights the scientific advances in profiling, risk stratification and innovative therapies for optimal care of these patients, with a focus on established and emerging biomarkers applicable for precision medicine and treatment selection.

All Resources are now open to delegates and ESMO Members

ESMO Colloquium supported by Eisai Europe Ltd. Management of patients with advanced endometrial cancer in the era of molecular oncology and immunotherapy

Watch the webcasts

Industry partners' Satellite Symposia

There are 142 resources available

36mo - maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (oc): 5-year (y) progression-free survival (pfs) by molecular subgroup in the paola-1/engot-ov25 trial.

Presenter: Antonio Jose Gonzalez Martin

Session: Mini Oral session

37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial

Presenter: Lingya Pan

Invited Discussant of abstracts 36MO and 37MO

Presenter: Rebecca Kristeleit

22MO - Homologous Recombination Gene Mutations in Uterine Serous Cancer: A Phenotype of the Hereditary Breast and Ovarian Cancer Syndrome?

Presenter: Muhammad Danyal Ahsan

38MO - Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial

Presenter: Céline Callens

39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer

Presenter: Romain Boidot

1MO - Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)

Presenter: Marcia Hall

Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO

Presenter: Iain McNeish

40MO - Targetable Gene Mutations in Mucinous Ovarian Cancer

Presenter: Sarah Levi

74MO - Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era: reassessing the Stage IVb designation

Presenter: Sean Koerner

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy .

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements:  Google Chrome 24+ ,  Mozilla Firefox 20+ ,  Internet Explorer 11 ,  Opera 15–18 ,  Apple Safari 7 ,  SeaMonkey 2.15-2.23

• Meeting Calendar
• OncologyPRO
• Past Meetings
• ESMO Congress 2023

ESMO Congress 2023: Abstracts

The abstract submission system is now closed..

View the abstracts in the online programme

Abstract submission deadlines

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters between 19 and 21 July 2023. Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end September.

Information for presenters

Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website in early August 2023, in the section “Information for Presenters”.

Abstract submission categories

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes .

The final late-breaking abstract deadline of 14 September 2023 is  under no circumstances  to be considered as an extension of the general submission deadline.

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Congress 2023.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Presentation of accepted abstracts

The ESMO Congress 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium - Oral presentations of cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
• Proffered Paper – Oral presentations of original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentation of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts will be published in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Publication schedule of accepted abstracts

Details regarding the publication of accepted abstracts are available here .

ESMO Merit Travel Grants

A limited number of Merit Travel Grants to ESMO Congress 2023 are available, upon application, to first authors under the age of 40 (forty) who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Congress 2023 Scientific Committee on a competitive basis from among the accepted abstracts.

EONS Novice Research Dissemination Award (NRDA)

The award is intended to give cancer nurses, who are relatively new to research, an opportunity to present their research at an international conference. Therefore, it is only open to cancer nurses who have not yet presented their research outside their own country.

Related Files

• ESMO Congress 2023 Abstract Regulations

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy .

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.